LSI Medience has presented equipment and a procedure to use human cardiomyocytes, derived from iPS cells, for drug testing. The cells are placed on the surface of the bottom of culture wells where electrodes have been located to capture electrical signals after stimulation. Results were similar to using human cardiomyocetes obtained from surgery and superior to animal cardiomyocytes. LSI Medience is a Mitsubishi company. The project was supported by NEDO in a program led by Professor Kenji Yasuda (Tokyo Medical and Dental University).
NEDO press release, July 2, 2014
LSI Medience develops ECG method for drug testing based on human cardiomyocytes derived from iPS cells